Table 1.

Patient characteristics

ID	Initial Gleason score	ISUP/ D’Amico	Ablation mode	Initial PSA ng/ml	Follow-up PSA ng/ml	Follow-up MRI-PI-RADS	Follow-up histopathology from MRI/ultrasound fusion-guided biopsy, infield (i) / outfield (o)	Specific characteristic
1	7a	2/ir	focal	8	4.22	4	7a (i + o)	artifact during TULSA
2	7a	2/ir	focal	7.1	4.1	4	7a (o)
3	7a	2/ir	focal	5	2.9	2	no malignancy
4	7a	2/ir	focal	10.3	1.59	2	no malignancy
5	6	1/lr	whole-gland	6.2	0.01	2	NA
6	7a	2/ir	whole-gland	7.05	0.15	2	no malignancy
7	7a	2/ir	focal	9.15	0.75	2	no malignancy
8	7a	2/ir	focal	8.1	4.6	2	no malignancy
9	6	1/lr	whole-gland	9.5	0.34	2	no malignancy
10	7a	2/ir	focal	5.5	5.5	2	NA
11	7a	2/ir	focal	3.46	4.23	4	7a (i + o)
12	7a	2/ir	focal	7.3	0.43	2	no malignancy
13	6	1/lr	focal	6.4	3.25	2	NA
14	7a	2/ir	whole-gland	8.8	0.71	2	NA
15	7a	2/ir	focal	9.1	2.37	2	no malignancy
16	7a	2/ir	focal	5.5	1.4	2	NA
17	7a	2/ir	focal	7.13	1.26	2	no malignancy
18	6	1/lr	focal	5		NA	NA	Lost to follow-up
19	7a	2/ir	focal	2.6	1.78	3	7b (o)
20	7a	2/ir	focal	5.33	3.05	4	NA	Lymph-node metastasis diagnosed with PSMA-PET
Salvage treatment after previous radiotherapy
21	No GS after radiotherapy		whole-gland, salvage	4.5	0.08	3	no malignancy	Later diagnosed with bone metastasis
22	No GS after radiotherapy		whole-gland, salvage	9.53	0.06	NA	NA	Patient refused MRI and Biopsy at PSA 0.1 ng/ml

PSA = prostate specific antigen, NA = not available, i = infield, o = outfield, D’Amico: lr = low risk, ir = intermediate risk, ISUP = International Society of Urological Pathology